Instil Bio Announces US FDA Clearance Of Investigational New Drug (Ind) Application For Axn-2510
July 2 (Reuters) - Instil Bio Inc TIL.O:
INSTIL BIO ANNOUNCES U.S. F.D.A. CLEARANCE OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR AXN-2510, A PD-L1XVEGF BISPECIFIC ANTIBODY, FOR A PHASE 1 TRIAL IN RELAPSED/REFRACTORY SOLID TUMORS
INSTIL BIO INC - TO INITIATE PHASE 1 TRIAL OF '2510 BEFORE END OF 2025
INSTIL BIO INC - INITIAL SAFETY AND EFFICACY RESULTS FROM PHASE 2 STUDY EXPECTED IN H2 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

Micron Stock Forecast: Can the AI Memory Super-Cycle Drive MU to $3,000 by 2030?

Dell Stock Analysis: Is It Still Undervalued and the Best AI Infrastructure Play by 2026?

Tesla Opens Up Over 2%, Shares Return to $400, Here Is What Investors Need to Note

Meta Stock Price Forecast 2026-2030: Can META Hit $1,000?

Tradingkey






